{"id":49153,"date":"2022-10-04T19:04:07","date_gmt":"2022-10-04T17:04:07","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-monoclonal-antibodies-mabs-market-research-report-2022-researchandmarkets-com\/"},"modified":"2022-10-04T19:04:07","modified_gmt":"2022-10-04T17:04:07","slug":"global-monoclonal-antibodies-mabs-market-research-report-2022-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-monoclonal-antibodies-mabs-market-research-report-2022-researchandmarkets-com\/","title":{"rendered":"Global Monoclonal Antibodies (mAbs) Market Research Report 2022 – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Monoclonal Antibodies Market Size, Share & Trends Analysis Report by Source Type (Chimeric, Murine, Humanized, Human), by Production Type (In Vivo, In Vitro), by Application, by End-use, by Region, and Segment Forecasts, 2022-2030”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe global monoclonal antibodies market is projected to reach USD 494.53 billion by 2030, at a compound annual growth rate (CAGR) of 11.30%\n<\/p>\n

\nIncreasing research and development activities aimed at the development of novel therapeutic monoclonal antibodies (mAbs) and supportive government initiatives for biologics production are anticipated to drive market growth in the forecast period.\n<\/p>\n

\nThe rising demand for personalized medicine is likely to positively affect the development of therapeutic mAb targeted therapies that are tailored to individual requirements. Moreover, the therapeutic use of mAbs offers several advantages such as fewer adverse effects, specificity of treatment, and large-scale production capabilities, as compared to conventional treatment options, and can significantly drive market growth.\n<\/p>\n

\nIn addition, several government entities are fueling clinical research activities and expanding the scope of applications for mAb therapies. For instance, in June 2022, the National Institutes of Health launched clinical trials for the evaluation of dupilumab, for the reduction of asthma attacks and the improvement of lung functionality in children.\n<\/p>\n

\nSimilarly, in March 2021, the U.S. Department of Health and Human Services invested USD 150 million in increasing patient access to monoclonal antibody therapeutics for COVID-19. Such initiatives are expected to increase the adoption of monoclonal antibodies and strengthen growth prospects.\n<\/p>\n

\nFurthermore, technological advancements in genetic engineering, DNA cloning, and various peptide and protein display technologies have led to the generation and optimization of recombinant mAbs. Demand for such recombinant antibodies is driven by increasing commercial prospects and quality requirements that may not be fulfilled by hybridoma technologies. Hence, with the increasing commercial viability of recombinant technologies, the market is expected to witness significant growth.\n<\/p>\n

\nThe COVID-19 pandemic has created several market expansion opportunities by fueling the development of several mAbs directed against the SARS-CoV-2 virus.\n<\/p>\n

\nAs mAbs represent a promising alternative for mitigation of the disease due to their safety and effectiveness, several mAbs such as Eli Lilly’s bebtelovimab, and GlaxoSmithKline & Vir Biotechnology’s sotrovimab have attained emergency use authorizations from the U.S. FDA. Such authorizations are likely to broaden the horizons for the growth of mAbs applications and propel market growth.\n<\/p>\n

\nMonoclonal Antibodies Market Report Highlights<\/strong>\n<\/p>\n